| Identification | Back Directory | [Name]
4(1H)-Quinolinone, 8-(4-fluoro-2-methylphenoxy)-2-(4-morpholinyl)- | [CAS]
351071-90-4 | [Synonyms]
TGX155
TGX-155
TGX 155
4(1H)-Quinolinone, 8-(4-fluoro-2-methylphenoxy)-2-(4-morpholinyl)- | [Molecular Formula]
C20H19FN2O3 | [MDL Number]
MFCD12922517 | [MOL File]
351071-90-4.mol | [Molecular Weight]
354.37 |
| Hazard Information | Back Directory | [Description]
TGX-155 is a selective inhibitor of PI 3-K. | [Uses]
TGX-155 (AZ12649385) is a selective inhibitor of PI3Kβ. TGX-155 has potential applications in antithrombotic therapy[1][2][3]. | [in vivo]
TGX-155 (1.5 mg/kg and 2.5 mg/kg; i.v.; single dose) significantly improves the cyclic flow reductions (CFRs) in rabbit carotid artery injury in a time-dependent and dose-dependent manner[3]. | [IC 50]
PI3Kβ | [References]
[1] Verheijen J C, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs[J]. Drugs Future, 2007, 32(6): 537-547.
[2] Nylander S, et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36. DOI:10.1111/j.1538-7836.2012.04898.x
[3] Sturgeon SA, et al. Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals. J Pharmacol Toxicol Methods. 2006 Jan-Feb;53(1):20-9. DOI:10.1016/j.vascn.2005.06.006 |
|
|